0001127602-12-007664.txt : 20120223 0001127602-12-007664.hdr.sgml : 20120223 20120223163216 ACCESSION NUMBER: 0001127602-12-007664 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120221 FILED AS OF DATE: 20120223 DATE AS OF CHANGE: 20120223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Haluska Frank CENTRAL INDEX KEY: 0001494892 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21696 FILM NUMBER: 12634272 MAIL ADDRESS: STREET 1: C/O ARIAD PHARMACEUTICALS, INC. STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884731 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223106987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174940400 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 form4.xml PRIMARY DOCUMENT X0304 4 2012-02-21 0000884731 ARIAD PHARMACEUTICALS INC ARIA 0001494892 Haluska Frank C/O ARIAD PHARMACEUTICALS, INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 1 SVP, Clinical R&D, CMO Common Stock 2012-02-21 4 M 0 4500 2.39 A 28365 D Common Stock 2012-02-21 4 S 0 4500 14.5059 D 23865 D Employee Stock Option (Right to Buy) 2.39 2012-02-21 4 M 0 4500 0 D 2009-06-12 2018-06-12 Common Stock 4500 25500 D Shares were acquired upon the exercise of outstanding stock options at $2.39 per share. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.18 to $14.905, inclusive. The reporting person undertakes to provide to ARIAD Pharmaceuticals, Inc. ("ARIAD"), any security holder of ARIAD, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2011. /s/Edward M. Fitzgerald, Attorney-in-Fact 2012-02-23